IMPACT OF BOVINE RESPIRATORY DISEASE COMPLEX

Bovine respiratory disease complex (BRDC) represents a major cause of economic loss in the beef and dairy cattle industries worldwide. In North America especially, this complex represents the leading cause of morbidity and mortality in 6- to 10-month-old beef cattle after entry into feedlots (United States Department of Agriculture, 2000). The financial losses are in part due to mortality, which can reach up to 69% in beef calves during first 2 months of arrival. Reduced growth performance and overall treatment costs (eg, metaphylactic and therapeutic use of antibiotics) for BRDC in a 1000-cattle feedlot has been estimated to be $13.90 per animal, assuming calves are slaughtered after 200 days on feed; labor and handling costs excluded.

The BRDC is a multifactorial disease arising from a combination of environmental, host, management, viral, and bacterial factors. The disease often develops along with stressful conditions such as weaning, shipping, commingling, dietary changes, and adjustments to the feed yard environment. These conditions favor viral infections of the lower respiratory tract that may become further complicated by Mannheimia haemolytica serotype 1 and Pasteurella multocida, both commensal bacteria of the nasal cavity. Viral infections well known to play an important role in the development of BRDC include bovine herpesvirus 1 (BHV-1), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea virus (BVDV), and parainfluenza virus type 3 (PI-3). Most cattle arriving at feedlot are routinely vaccinated against these viruses, which
has led to a decrease in incidence of these primary pathogens. However, other viral agents continue to cause substantial losses due to BRDC (Sanjay Kapil, unpublished data, 2008). There is currently a growing body of evidence\textsuperscript{1,4–9} showing that bovine coronavirus (BCoV) may be involved in the development of BRDC.

**BOVINE CORONAVIRUS**

Animal coronaviruses are divided into 3 antigenic groups: Group 1 has no hemagglutinin-esterase (HE), and important members of this group are feline infectious peritonitis and transmissible gastroenteritis virus in swine; Group 2 has HE and contains BCoV\textsuperscript{10}; and Group 3 contains avian virus–like infectious bronchitis virus. There are only a few studies on molecular epidemiology of BCoV.\textsuperscript{11–13} These studies have targeted the spike gene of BCoV for phylogenetic analysis because it is the most critical surface protein that binds to the receptor N-acetyl-9-O-acetyleneuraminic acid of the virus.\textsuperscript{14} The Japanese BCoV isolates (1999–2008) cluster in 4 phylogenic groups. Japanese isolates collected after 2005 were included in antigenic Group 4.\textsuperscript{11} In another study from South America, the Brazilian BCoV isolates were genetically divided into 2 groups.\textsuperscript{12} At present, there are no large-scale studies that have compared the BCoV isolates from America and other parts of the world.

**Epidemiology of Bovine Coronaviruses**

Bovine coronavirus is widespread in the cattle population, resulting in economic losses to the beef and dairy industry throughout the world. The virus has been detected on all continents and there is serologic incidence (>90%) that suggests most cattle become exposed to BCoV in their lifetime. In a recent study, the presence of BCoV in lungs was second in incidence after bovine herpesvirus.\textsuperscript{15} Both in beef and dairy herds, BCoV can be associated with calf diarrhea, calf respiratory disease, winter dysentery, respiratory disease in adult cattle, and combined pneumonia and diarrhea in calves and adults.\textsuperscript{16,17} The coronavirus strains isolated from nasal secretions and lung tissues of cattle with fatal cases of pneumonia have been classified as bovine respiratory coronaviruses (BRCoV). The coronavirus strains isolated from neonatal calves and adult cattle with diarrhea are referred to as bovine enteric or enteropathogenic coronaviruses (BECoV).\textsuperscript{18} Furthermore, for clinical purposes, BECoV can be further subdivided into BCoV-induced calf diarrhea (BCoV-CD) and winter dysentery (BCoV-WD). The clinical manifestation of the disease syndromes are not solely related to the virus itself but also to host and environmental factors; for example, the immunologic status of the animal, environmental temperature, and secondary coinfections with other pathogens.\textsuperscript{19}

Researchers have debated over last several years whether BCoV isolated from the gastrointestinal and respiratory tracts of affected cattle are the same virus or are dissimilar, perhaps altered in biologic, antigenic, and genetic (sequence) properties. Several publications have supported the hypothesis that enteric and respiratory BCoV may be the same virus detected at different stages of its infectious life cycle.\textsuperscript{20–29} Early reports\textsuperscript{28,29} suggested antigenic and genomic similarity between isolates of BCoV from the respiratory and enteric tracts of cattle. Later studies\textsuperscript{5,25,30,31} identified differences in antigenic, genomic, and culture characteristics between the 2 groups of BCoV isolates. At present, it is still unclear whether isolates of BRCoV and BECoV can be distinguished antigenically.\textsuperscript{30,32} Specific factors associated with their respective tropism for the respiratory or digestive tracts are also undefined. The reasons for scientific uncertainties\textsuperscript{33} include that BCoV RNA genome is the longest (approximately 32,000 bases) compared with other animal viruses and is capable of
further evolution. In addition, the number of complete sequences published on this virus is scarce, for example, 4 isolates comprising Mebus (U00735), Québec (AF220295), and Louisiana (NC_003045) enteric and respiratory BCoV. Due to the insufficient number of BCoV isolates sequenced, an accurate comparison of BECoV and BRCoV origin is therefore difficult to establish. Moreover, there are temporal changes and geographic differences that further confound the conclusions.34

Coronaviruses within the antigenic group 2 are known to cross between species. Beyond cattle, other domestic animals (horses, water buffalo,35 camel,36 New World camelids37), and wildlife (deer, elk38) and zoo animals (giraffe39) also have BCoV-like viruses that can infect calves because these viruses are genetically related to BCoV. The infection of small ruminants with coronavirus is less common. There is seasonal variation in the incidence of BCoV diarrhea. Stressors, including inclement weather40 and shipping, are important contributing factors that may exacerbate disease from BCoV and BRCoV infections.

TRANSMISSION AND PATHOGENESIS

Infection is primarily via feco-oral and to a lesser extent, respiratory (aerosol) routes.20,23,41–43 Bovine enteropathogenic coronavirus is shed in mucosal secretions from the upper respiratory tract and excretions from the gastrointestinal tract.43–45 Bovine coronavirus is ubiquitous in the cattle population and persists in adults as subclinical infections.44,46 However, under stressful conditions adult cattle can shed BCoV in feces and nasal secretions.46 Most often, transmission of BECoV is horizontal, and occurs from carrier dam to offspring postpartum47 or from clinically or chronically infected calves housed in proximity to naïve ones. Evidence of vertical transmission has not been reported.47 In close herds, respiratory tract infections constitute a source of BCoV transmission to cows or young calves.26 Experimental inoculation of BCoV-CD and BCoV-WD strains of BCoV in adult dairy cows has been associated with development of clinical signs and viral shedding in the feces.48

Bovine coronavirus is a pneumoenteric virus that replicates in the enterocytes of the intestinal tract and the epithelium of the upper respiratory tract.34,43 More specifically, the virus has been shown to replicate in the respiratory tract of calves, with viral antigen detected in the epithelium of the lung, trachea, and nasal turbinates.7,23 Park and colleagues34 have suggested that BCoV infections of the respiratory tract may occur via inhalation, via monocyte-associated viremia that may originate from the intestines after ingestion of BCoV, or via cell-free viremia. In one study, peak of BCoV shedding in nasal secretions occurred at 3 days before arrival and in feces, at 3 days following entry to feedlot, under field conditions.20 Researchers have proposed that replication and shedding of BCoV in nasal secretions is first initiated through the respiratory tract (oropharynx) then spreads to the gastrointestinal tract through the swallowing of large quantities of virus with subsequent shedding in the feces.20,49 Other reports have documented BCoV shedding in both nasal passages and feces within the same animal concurrently.20–22 Respiratory disease can be consistently reproduced experimentally in young calves using a pneumoenteric BCoV, Minnesota-1988 (MN-1988).50,51

Coronavirus is an enveloped single-stranded RNA virus, and is not as stable in the environment as rotavirus.47 However, in the presence of organic material, these viruses may remain infectious for up to 3 days. Of note, coronaviruses can bind extremely well to clay, clay minerals, and charcoal in vitro, with an adsorption of 99%.52 These findings suggest that clay soils can concentrate BCoV on its surface,
which can be clinically relevant, as the animals grazing on these types of soils could get exposed to infectious doses of BCoV.

Dogs may play a role in BCoV infection; canine respiratory coronavirus is genetically related to BCoV and has been found in kennel cough cases in Europe and the United States. Dogs may represent a passenger of the BCoV on farms.

**ROLE OF BOVINE CORONAVIRUS IN BOVINE RESPIRATORY DISEASE COMPLEX**

Within the last 2 decades, BRCoV has been associated, either alone or along with other respiratory pathogens, with the emergence of shipping fever pneumonia of beef cattle after transport to feedlot and enzootic calf pneumonia. However, there is still conflicting information in the literature regarding the true role of BCoV as a pathogen of the respiratory tract in calves and feedlot cattle. Several investigators have shown that BCoV may represent one important pathogen involved in the development of BRDC, whereas others could not detect any correlation between BCoV shedding and respiratory tract disease under field conditions. At least 3 studies failed to reproduce clinical signs of BRDC in calves after experimental inoculation with BCoV, which may be due to choice of the viral isolate used to experimentally reproduce the infection. In contrast, 2 research groups reported that BCoV can be isolated from clinically healthy cattle, whereas others have failed to detect the presence of BCoV in feedlot calves experiencing respiratory tract disease.

In 1995, it was reported that all 4 of Koch’s postulates to associate BCoV with upper and lower respiratory tract disease in neonatal calves were fulfilled. However, these postulates do have limitations when being applied to complex diseases such as BRDC in adult cattle. Investigators recently supported BRCoV as the primary inciting cause of the 2 epizootics of shipping fever pneumonia they investigated, based on Thomson’s modification of Evans’ criteria of causation.

There is evidence that BRCoV can be repeatedly isolated in the majority of calves sampled soon after feedlot entry. Cattle shedding BCoV nasally and seroconverting within the first month after entering the feedlot are at increased risk for respiratory disease and 1.6 times more likely to require subsequent treatment for BRDC. Reported rates of nasal BCoV isolation in several studies have ranged from 8.1% to 60%. In one report, cattle that shed BCoV in their nasal secretions during the first 28 days after feedlot arrival were 2.2 times more likely to have pulmonary lesions at slaughter compared with nonshedders. Although there was no statistical association between clinical signs and virus shedding, another trial reported that feedlot cattle shedding BCoV nasally were 2.7 times more likely to show respiratory signs, and those shedding BCoV fecally were 2.5 times more likely to develop diarrhea.

Most of the calves shedding BCoV nasally at arrival have low but detectable antibody titers at arrival and typically seroconvert within the first 3 to 4 weeks after feedlot entry, suggesting that they are often infected with BRCoV at times when respiratory tract disease is likely to occur. Two published seroepidemiologic studies found that although higher antibody titers against BCoV at feedlot arrival were significantly associated with a decreased subsequent risk of treatment for BRDC within cattle groups, there was no association between evidence of recent infection (titer increase) and the incidence of BRDC. In contrast, several investigators have shown that high antibody titers against BCoV at feedlot arrival have consistently been associated with a decrease in BCoV infection, shedding, or both, under field conditions or in experimental challenge studies. Decreased BCoV shedding in nasal secretions and protection
against BCoV infection have been associated with high serum antibody titers (geometric mean: GMT) ranging from 1600 to 2,26220,21,26,32 at feed yards entry. Moreover, cattle entering feedlots with high antibody titers against BCoV appeared less likely to seroconvert to BCoV than cattle without detectable BCoV titers at arrival.1,59,62

Depending on the feedlot, active immunity was reported to be associated with moderate to high seroconversion (4-fold increase in BRCov antibody titers) in the face of clinical respiratory tract infection in 58% of 814 cattle,59 61% of 604 cattle,1 91% of 85 cattle,32 and 90% in 852 cattle spread among 3 different feed yards, and in 95% of 57 cattle.21

Economic Impact of Bovine Respiratory Coronavirus

Several investigators have shown that BCoV-associated BRDC is correlated with decreased performance in feedlot cattle.1,21,32 According to a published report,1 shedding of BRCov correlated with a reduction in weight gain. One study involving 837 calves in 4 feedlots from 2 states (Ohio, Texas) showed that the BCoV shedding or seroconversion status did not affect the average daily gain.6 However, shedding of BCoV in feces of 6- to 7-month-old cross-bred feedlot steers was associated with a reduced weight gain of 8.17 kg (17.9 lb) during a period of 21 days.21 In an Ohio feedlot,32 calves that seroconverted to BCoV gained 5.9 kg (13 lb) (26%) less than the nonseroconverted group during the first 21 days after arrival to the feedlot. Seroconversion to BCoV was almost associated significantly (P<.06) with reduction in weight gain but not with clinical signs. In one report involving 203 feedlot calves from New Mexico and Arkansas, animals shedding BCoV in nasal secretions, feces, or both, gained on average 8 kg (17.64 lb) less than calves that were not shedding the virus over a 35-day period following entry.20 Therefore, BCoV infections may contribute directly to economic losses in feedlot cattle by impacting weight gains or, similar to other respiratory viruses, by predisposing cattle to secondary bacterial infection.

Clinical Manifestation of Bovine Respiratory Coronavirus

Under experimental conditions, neonatal, colostrum-deprived calves inoculated with BCoV can develop respiratory distress, such as wheezing and open-mouth breathing.51 Under natural conditions, calf pneumonia caused by BRCoV can be observed in calves aged 6 to 9 months. Affected animals may develop fever,23 serous to mucopurulent nasal discharge,66 coughing, tachypnea, and dyspnea.5,7

Respiratory illness caused by BRCoV in an Ohio feedlot was characterized by coughing and nasal discharge along with diarrhea, and was observed in 62% and 77% of cattle.32 Diagnostic investigation of 214 BRDC outbreaks in Italy was associated with an 85% morbidity rate in those due to BRCoV infection.67 The mortality rate due to BCoV infection can be high.4,67

In another study,2 viral respiratory disease was seen in 19% of the animals and accounted for 20% of the mortality in feedlot cattle. Bovine respiratory coronavirus was detected in approximately 2% of the cases based on virus isolation in cell culture. If fluorescent antibody testing or reverse transcriptase-polymerase chain reaction (RT-PCR) were used for detection of BRCov, the actual incidence may have been higher. The reason RT-PCR gives higher estimates of BCoV infection in lungs is because, at core body temperature, the replication of BCoV may be diminished. However, in the upper cooler parts of the respiratory tract, replication of the virus is abundant and can become the source of the virus for the lower respiratory tract.
OTHER CLINICAL SYNDROMES ASSOCIATED WITH BOVINE CORONAVIRUS

Bovine Enteropathogenic Coronavirus Associated with Diarrhea in Calves

Pathogenesis and pathology

Enteropathogenic bovine coronavirus is widely recognized as an important primary pathogen causing neonatal calf diarrhea (BCoV-CD). The pathology of BCoV-CD is often more severe than that of rotavirus, resulting in a mucohemorrhagic enterocolitis. Infection leads to destruction of the absorptive intestinal villous epithelial cells. Virus replication is cytocidal and initially occurs throughout the length of the villi in all levels of the small intestine, eventually spreading throughout the large intestine up to the end of the large colon and rectum, causing a malabsorptive diarrhea. Large concentration of BCoV can be typically found in the spiral colon. Infected epithelial cells die, slough off, and are replaced by immature cells. Stunting and fusion of adjacent villi and atrophy of colonic ridges may be seen on microscopic examination of BCoV-infected small and large intestine, respectively. In case of malabsorptive diarrhea caused by BCoV, the fluid load in the gut lumen can be further exacerbated by the compensatory hyperplasia and secretions from the crypt epithelial cells. The absorptive and digestive capacity of the intestinal tract is therefore compromised by loss of surface area and presence of immature cells, which are unable to secrete the normal digestive enzymes. Lesions and consequences are most severe in younger animals.

Continual enteral feeding may result in more nutrients presented to the small intestine than the damaged villi can absorb. Undigested nutrients are fermented in the large intestine, promoting bacterial overgrowth and production of organic acids, especially D-lactate. The osmotic effects of the unabsorbed nutrients draw water into the gut lumen and contribute to the diarrhea. Over time, if fluid losses exceed intake, extensive water (mainly from the extracellular space), sodium, chloride, potassium, and bicarbonate loss occurs. Dehydration and metabolic acidosis subsequently develops. The acidosis has several causes including fecal bicarbonate loss, endogenous L-lactic acid production in response to dehydration and poor tissue perfusion, and local D-lactic acid production within the gastrointestinal tract.

Epidemiology

Bovine coronavirus causes enteritis in both dairy and beef herds, with naturally occurring cases showing clinical signs of disease between 5 and 30 days of life. According to the BCoV enzyme-linked immunosorbent assay (ELISA) database from Kansas State University, Manhattan, KS, 1 in 3 case of calf diarrhea in the age group of 1 to 9 weeks can be due to BCoV. Clinical disease may occur as young as 24 hours of age in colostrum-deprived calves, and as late as 5 months of age. Once infected, a calf can excrete high levels of virus (eg, 1 billion virus particles per ml of feces) within 48 hours after experimental infection, and this may persist up to 14 days. Clinically recovered calves may continue to shed low levels of virus for weeks. Of note, BECoV may be detected in the feces of both diarrheic and healthy calves, with clinically diarrheic calves more commonly tested positive (incidence: 8%–69%) compared with healthy calves (incidence: 0%–24%).

BECoV has been detected intermittently at very low levels in the feces of more than 70% of clinically normal cows, despite the presence of specific antibodies in serum and feces. In one study involving 132 cows and heifers with no previous BCoV vaccination history, all were found to have substantial levels of antibodies. In non-vaccinated cows, the rate of virus excretion has been reported to increase by 50% to 60% during the winter months, by 65% at parturition, and by 71% 2 weeks postpartum.
postpartum. This virus is more stable in the colder climates, due to lower ambient temperature and reduced ultraviolet light levels, and has been reported to cause winter dysentery in adult cattle especially after snow storms or sudden changes in ambient temperatures. Calves born to BCoV carrier dams have a significantly higher risk of developing BCoV diarrhea due to periparturient exposure from fecal contamination of the perineum, teats, and the calving area.

**Economic impact**

Diarrhea remains an important cause of illness and death in young beef calves. Economic losses associated with the disease include decreased performance, mortality, and the expenses of medication and labor to treat sick animals. Annually, beef cattle herds may experience death rates of 5% to 10% or greater, and sometimes up to 100% morbidity.

**Clinical signs**

The severity of the BECoV enteritis depends on the age of the calf at time of infection, its immunologic status, the size of the infective dose, and the virulence of the BECoV strain in question. As a general rule, the severity of the disease is increased and the incubation period is shortened in younger compared with older calves, especially those with failure of passive transfer. A yellow to blood-stained mucus-containing diarrhea initially develops, which then progresses to a profuse watery diarrhea. When the fluid intake is insufficient to meet the losses, affected animals become clinically dehydrated, depressed, weak, and hypothermic, and their suckle reflex is loosened. The majority of calves recover, but a few may develop pyrexia, recumbency, and progression to cardiovascular collapse (from dehydration, acidosis, and associated hyperkalemia), coma, and death if the diarrhea is particularly severe and left untreated. Some of the BECoV-infected calves may develop a pneumoenteritis syndrome in which both diarrhea and mild signs of respiratory tract disease are present. Affected calves shed the virus not only in their feces but also in their nasal secretions.

**Differential diagnosis**

Other enteropathogens, such as rotavirus, are frequently detected in feces from BECoV-infected calves. Rotaviruses are the leading cause and coronaviruses are a major contributor of calf diarrhea; however, infections with BCoV are more severe because they affect both the small and large intestines. In most outbreaks of acute undifferentiated BCoV-CD, calves frequently shed 1, 2, or multiple agents simultaneously. Mixed infections are typically associated with more severe disease. Researchers have reported that calves shedding 2 or more pathogens were 6 times more likely to develop clinical diarrhea compared with the ones that shed only one or no pathogen. Besides rotavirus and coronavirus, Cryptosporidium parvum, enterotoxigenic Escherichia coli, and Salmonella spp are recognized as the major infectious agents associated with diarrhea in calves. Without specific testing, it is usually impossible to make a definitive etiologic diagnosis solely based on clinical signs. Signs of colitis in calves including tenesmus and presence of frank blood and mucus in the feces may be present with Salmonella spp, coronavirus, BVDV, enteropathogenic E. coli, or coccidian infection.

**Bovine Enteropathogenic Coronavirus Associated with Winter Dysentery in Adult Cattle**

**Etiology, pathogenesis, and pathology**

During the past 2 decades, evidence has accumulated implicating BCoV as a cause of winter dysentery (BCoV-WD). Winter dysentery is a sporadic acute,
contagious hemorrhagic enterocolitis of cattle that occurs in epizootic fashion in a herd. The pathophysiological characteristics of BCoV infection can be attributed to lesions of the colonic mucosa. The intestinal lesions are comparable with those observed in calves with BECoV-induced diarrhea. Epithelial cells of colonic crypts are destroyed by viral action, leading to degeneration, necrosis of crypt epithelium, and petechial hemorrhage, without involvement of the Peyer patches. Fine streak of frank blood or large blood clots may be present in the lumen of the spiral colon, distal colon, and rectum. Even though histologic changes have been observed predominantly in the colonic mucosa, blood from the distal duodenum was observed aborally in cattle that died of winter dysentery. Loss of intestinal mucosal epithelium from colonic crypts leads to transudation of extracellular fluid and blood. The respiratory tract of BCoV-WD affected animals may show hyperemia of the tracheal mucosa and localized foci of pneumonia.

**Epidemiology**

In the United States, BCoV-WD is more common in the northern states; however, it has been reported throughout the world including Australia, Sweden, the United Kingdom, Israel, France, Belgium, Italy, Japan, Cuba, and Canada. The disease occurs usually during the colder months of the year and often coincides with close confinement of cattle. Only seldom have reports described BCoV-WD occurring during the warmer season. The disease is characterized by a high morbidity rate ranging from 50% to 100%. In contrast, mortality rate is usually low, typically less than 2%, with only a few reports describing case fatality associated with this virus. Winter dysentery outbreaks are predominantly seen in young postpartum adult dairy cows, which then experience a marked drop in milk production, resulting in 25% to 95% milk losses. In the acute stage of the disease, this may last 3 to 6 days. When it persists for a few days to a week or more after the outbreak terminates, economic loss can be substantial. Though infrequent, BCoV-WD has been also observed in adult beef cattle and in 6- to 9-month-old feedlot calves. Although most reports indicate this to be a disease of adult cattle, in a herd outbreaks of mild diarrhea may be observed in heifers and calves as young as 4 months old.

The incubation period for BCoV-WD ranges from 2 to 8 days. In small housed herds, the incidence of diarrhea during an outbreak begins with the explosive appearance of signs in 10% to 15% of animals on the first day. By the second day, another 20% to 40% are affected; morbidity reaches 100% by the fourth day. By the end of the week the first affected animals are completely recovered, and only a small number of new cases occur. Within 2 to 3 weeks of the onset of diarrhea, all animals have recovered. In large herds the outbreak may be prolonged for 6 to 8 weeks. This scenario is typical of a herd that had not experienced an epizootic of winter dysentery during the preceding few years.

Epidemiologic studies of BCoV-WD have suggested that various host and environmental factors may contribute to the appearance of the disease. These factors include the age and reproductive status of the animal, with recently calved 2- to 6-year-olds being the most susceptible, and previous history of a BCoV disease outbreak in herds comprising more than 60 cows. Environmental risk factors for BCoV-WD include drop in atmospheric temperature, close confinement, poor ventilation, and using manure-handling equipment to handle feed. Although nonspecific, historical findings associated with BCoV-WD outbreak may include recent stressors (eg, inclement weather), incoming farm visitors who have had close contact with cattle, or introduction of a newly purchased animal.
**Clinical signs**

Winter dysentery is an acute diarrheic disease of predominantly dairy and infrequently beef cattle characterized by an acute onset of dark brown, often hemorrhagic, watery, and commonly profuse diarrhea accompanied by some degree of anorexia and depression. The diarrhea may contain a slight to copious amount of mucus. The amount of blood varies from case to case and ranges from just visible flecks or streaks to large clots, or it may be uniformly mixed into the feces. Pyrexia is usually not present during the diarrheal phase of the disease, although it has been reported to precede it by 24 to 48 hours or have no consistent relationship. Mild to moderate signs of respiratory disease (e.g., cough, nasal discharge) have been inconsistently observed preceding or concurrent with the diarrhea.

As mentioned previously, milk production can be significantly reduced in affected lactating cows. A few cases may show mild colic signs while other animals appear weak. If the diarrhea is severe or persists longer than 1 or 2 days, dehydration and secondary polydipsia may develop. Ruminal motility is commonly reduced and intestinal borborygmi may be increased.

The odor in a barn during an outbreak of BCoV-WD has been described as musty, fetid, and unpleasantly sweet. The period of illness in an individual is brief, and within a herd the outbreak usually lasts less than 2 weeks. According to most reports the shorter and less severe the diarrhea, the more rapid the recovery and return to normal condition ensues.

**Differential diagnosis**

Winter dysentery is usually recognized by the clinical syndrome described here and by exclusion of other causes of acute and contagious diarrhea of adult cattle. Diarrhea caused by BVDV, coccidiosis, and salmonellosis must be considered in the differential diagnosis of BCoV-WD. PCR, virus isolation or immunohistochemistry (ear notch), fecal floatation, and fecal bacterial culture should be performed to rule out BVDV, coccidiosis, and salmonellosis, respectively. Specific hematologic changes that would be consistent with a diagnosis of BCoV-WD have not been reported. If significant dysentery persists for longer than a day, anemia may develop due to significant blood loss.

The disease syndrome is more often than not diagnosed on the basis of history of acute onset of diarrhea and dysentery affecting at least 15% of the adult cattle herd; rapid spread causing a drop in milk production of 10% or more; resulting in less than 2% fatalities. The rapid occurrence of multiple cases within a herd combined with spontaneous recovery over a few days and absent oral mucous membranes erosions suggests BCoV-WD.

**DIAGNOSIS OF BOVINE CORONAVIRUSES**

Because of similarity of clinical signs induced by various infectious agents, physical examination of calves or adult cattle with respiratory tract disease or diarrhea is not sufficient for diagnosis of BRCoV infection. Bovine respiratory coronavirus can only be identified through laboratory confirmation of appropriate specimens submitted. Suggested antemortem samples for BRCoV infection in calves and adult cattle include nasal swabs submitted in phosphate-buffered saline (pH 7.2) or normal saline in red-top tubes. Oropharyngeal fluid collected with a probang cup can be used to diagnose BRCoV in adult cattle. Trachea (upper one-third), and lungs can be collected at necropsy. However, the distribution of BCoV in the lungs is focal and thus, it is critical that multiple pieces are submitted for virus detection. Viral antigen has been detected in the apical and middle lung lobes of calves infected...
experimentally with BCoV (MN-1998) whereby 5% to 10% of the macrophages were positive for BCoV (Fig. 1) (Tawfik Aboellail, and Sanjay Kapil, unpublished data, 2000). Other suitable respiratory tissues include nasal turbinates, but these may be difficult to sample. Nasal turbinates and nasal glands have been found to be strongly positive for BCoV antigen using immunohistochemistry and immunofluorescence (Figs. 2 and 3).\textsuperscript{117} Spiral colon is the sample of choice for detection of BECoV at necropsy because the virus persists in that specific location for the longest time after oral infection.\textsuperscript{50} A fresh fecal sample collected directly from the rectum can be also included, as cattle with respiratory disease commonly shed the virus in the feces concomitantly. Approximately 2 to 5 g of fresh feces can be sent to the laboratory in wide-mouth jars. It is important to submit all tissue and fecal samples over ice-packs using overnight delivery to increase the likelihood of BCoV detection.

Diagnostic tests of choice for BCoV are antigen-capture ELISA\textsuperscript{118} using Z3A5 monoclonal as capture antibody. Another useful diagnostic reagent is 8F2 monoclonal antibody (MoAb), which binds to nucleocapsid protein of BCoV, the most predominant protein of the virus (www.ruraltechninc.com).\textsuperscript{119} The 8F2 reacts with the viral antigen in formalin-fixed intestines (see Fig. 3) and lungs. The 8F2 MoAb reacts with a conserved epitope of the antigenic group 2 coronaviruses such as alpaca, equine, camel, and elk coronavirus. Other laboratory-based methods for detection of BCoV include hemagglutination assay using mouse erythrocytes; this method, with modification (such as slide agglutination test), can be used in developing countries and for animal-side testing. RT-PCR assays can be used for sensitive detection of BCoV in clinical samples. The targets are the conserved nucleocapsid gene for detection of the virus and spike gene for epidemiologic investigation and strain differentiation. At present, there is no commercial test available for BCoV antigen detection in the United States. However, lateral flow immunoassays (LFT) are useful cow and calf-side tests, and are available in European Union for BCoV antigen detection in the feces.\textsuperscript{120}

Based on experimental infection with a pneumoenteric isolate of BRCoV, neonatal colostrum-deprived calves develop interstitial pneumonia (Fig. 4) and emphysema, pulmonary congestion and hemorrhage (Fig. 5), and edema of the interlobular septa, with the ventrolateral areas of the lungs being mainly affected.\textsuperscript{45} Most of these calves showed cryptitis in the spiral colon on histologic examination (Fig. 6).

Fig. 1. BCoV antigen in macrophages was detected by immunohistochemistry (8F2) in formalin-fixed section of lungs from an adult cow showing clinical signs of lower respiratory tract infection.
TREATMENT OF BOVINE CORONAVIRUS INFECTION

Bovine Respiratory Coronavirus

There are no specific antiviral treatments for BCoV infection in beef or dairy cattle. However, because viral infection can predispose to development of secondary bacterial infection in the lungs and the fact that BCoV cannot be differentiated clinically from other important viral or bacterial pathogens involved in BRDC, parenteral antibiotic therapy administered early in the disease process, at sufficient dosage and duration, is recommended to prevent or limit the development of bacterial pneumonia in cattle with viral respiratory tract infection. The use of nonsteroidal anti-inflammatory drugs

Fig. 2. Immunohistochemistry on formalin-fixed section of the intestine submitted from a calf stained with 8F2 anti nucleoprotein antigen of BCoV. Brown staining in the crypts indicates positivity for BCoV.

Fig. 3. Nasal cells positive for BCoV by direct fluorescent antibody test using anti-BCoV fluorescein isothiocyanate conjugate. Swab was collected from a calf experimentally infected with a pneumoenteric BCoV (MN-1988).
(NSAIDs) such as flunixin meglumine (Banamine), currently labeled specifically for the control of pyrexia associated with BRDC in the United States, has been shown to be useful in other viral pneumonias (eg, PI-3) by improving clinical signs and reducing lung consolidation. However, flunixin meglumine may not be cost-effective when used in large feedlots and can potentially lead to renal toxicity or abomasal ulceration if overdosed, used for prolonged periods of time, or used in severely dehydrated animals. Approved in the European Union for use in food animals, a single injection of the long-acting NSAID meloxicam (Metacam) administered as an adjunct therapy for BRDC in feedlot cattle resulted in substantial pharmacoeconomic benefit. Based on a limited number of publications and due to its impairment of immune function, it is usually not recommended to use corticosteroids as an adjunct therapy for the treatment of undifferentiated pneumonia in feedlot cattle. Other ancillary therapies suggested for treatment of BRDC have included Vitamin C or B injection, bovine growth hormone, and immunostimulants.

![Fig. 4. Interstitial pneumonia in a calf experimentally infected with MN-1988 pneumoenteric BCoV isolate.](image1)

![Fig. 5. Pulmonary hemorrhages in a calf inoculated with a pneumoenteric isolate of BCoV.](image2)
respiratory vaccine (IBR, BVDV, BRSV, PI-3) at the time of BRDC therapy, antihista-
mines, anthelmintics (eg, levamisole), probiotics, and oral electrolytes; however, no
published data are available to support their use.123,124

Supportive therapy represents an important component of BRDC treatment, and is
aimed at relieving stress and allowing time for the sick animal to foster its own resis-
tance.55 All sick cattle should be provided shelter to avoid adverse weather conditions
and not be crowded while isolated in designated hospital pens. These cattle should be
provided best-quality, highly palatable feed, and easy access to fresh drinking water
and mineral mixes.

Bovine Enteropathogenic Coronavirus

**Calf diarrhea**

Treatment of calves suffering from BECoV enteritis is entirely supportive and should
be instituted based on clinical signs and, if possible, laboratory data including blood
gas analysis, to determine the extent of metabolic acidosis, blood glucose and elec-
trolyte abnormalities, and testing for the presence of BECoV in feces. Treatment goals
should follow the same general guidelines as those recommended for diarrhea caused
by other enteropathogens. In brief, treatment should include correction of fluid loss
and dehydration, electrolyte imbalance, acidosis, hypoglycemia, and hypothermia.
This correction is achieved primarily through administration of oral electrolytes or
intravenous polyionic isotonic crystalloid fluid therapy, and provision of a warm and
dry environment. Selection of the type of fluids, the amount to provide, and rate
and route of administration is based on the age and weight of the animal(s), severity
and duration of clinical signs, level of metabolic acidosis, and whether the affected
calf has a suckle reflex. The authors refer the reader to other in-depth reviews on
the treatment and management of diarrhea caused by BCoV in calves.70,93,125,126

**Winter dysentery**

Most animals with BCoV-WD recover spontaneously in a few days without specific
treatment, but in some cases supportive therapy may be indicated.113 Many palliative
treatments have been recommended and used over the years, including intestinal astringents, protectants, adsorbents, and antibiotics. Based on 30 years of observations, Roberts112 considered none of these treatments altered the course of the disease. Abundant provision of fresh drinking water, palatable feed, and free-choice salt is the most useful nonspecific therapy. Oral or intravenous fluid therapy may be indicated, depending on the extent of dehydration. The occasional animal with prolonged or severe dysentery may necessitate a whole blood transfusion.

**STRATEGY FOR CONTROL AND PREVENTION OF BOVINE CORONAVIRUS**

There are no specific and effective methods to control or prevent disease caused by BCoV. Identification and isolation of carrier cows and calves should in theory decrease the pathogen load in the environment; however, in practice this approach may be unattainable as BCoV infections are typically widespread, even in close herds.42,87,92 Therefore, management procedures must emphasize enhancing passive and active immunity to prevent clinical disease, minimizing stressors, and reducing the exposure of young susceptible calves. Protection relies on continual presence of a protective antibody within the gut lumen, which is passively acquired from the dam in the form of specific neutralizing antibodies (predominantly immunoglobulin type 1 [IgG1]) ingested in the colostrum or milk.78,90 This IgG isotype has activity against the spike protein of BCoV.

Lactogenic immunity will vary depending on the levels of maternal BECoV antibodies present in the serum and colostrum.43 Ingestion of colostrum from an immune cow prevents the shedding of BCoV in the feces, and reduces the risk of spread to other herd mates (including calves) and environmental contamination. However, when colostral antibody wanes, calves become susceptible to BCoV infections, especially the ones born to primiparous cows.46

In problem herds, the immune status of susceptible calves may be raised either via vaccination of pregnant cows to increase the level of passively acquired immunity, or via oral vaccination of newborn calves to stimulate active immunity.78 Oral administration of spray-dried bovine serum supplemented calf milk replacer (from Land-O-Lakes, Kansas City, MO) has been associated with a decrease in the severity of the clinical signs in calves experimentally inoculated with BCoV (Sanjay Kapil, unpublished data, 1999).127 This protection may vary and is dependent largely on the total amount of antibody titer against BCoV present.

Factors that can have an adverse effect on the calf’s immune status include dystocia, exposure to environmental extremes such as hot, cold, wet, or windy conditions, overcrowding, excessive handling in the postnatal period, and direct exposure to pathogens.82,128,129 As a result, newborn calves should be placed in sheltered environments, ideally on dry bedding, while trying to keep the concentration of enteric pathogens present at a minimum. Management strategies or husbandry practices to reduce exposure of the neonate to infected fecal material or aerosol primarily include thorough cleaning and disinfection of calving or nursery areas, adequate ventilation, physical isolation of clinically affected animals,130,131 and noncommingling between younger and older calves, as described in the Sandhills calving system.132 The authors refer the reader to other review articles for more specific biosecurity and biocontainment recommendations to minimize gastrointestinal pathogen exposure for both dairy or beef herds calving in confined areas or at pastures.70,93,133

**Disinfection**

As with any infectious disease, isolation and segregation of affected animals in quarantine, sanitation, and disinfection of footwear and equipment may help limit the
spread of the disease. Bovine coronavirus is an enveloped RNA virus and is more sensitive to soaps, lipid solvents such as ether or chloroform, and common disinfectants such as formalin, phenol, and quaternary ammonium compounds, compared with nonenveloped viruses. Removal of organic material is critical before application of disinfectant for maximal effectiveness. Bovine coronavirus can remain infectious for up to 3 days in soil, feces, and bedding materials.

**Bovine Coronavirus Vaccines**

**Vaccines for bovine enteropathogenic coronavirus**

There are 2 types of vaccines commercially available for the prevention of enteric disease caused by BCoV in neonatal calves. One is a killed vaccine (Scour-Guard 3(K), Pfizer Animal Health, NY; Guardian, Intervet/Schering-Plough Animal Health, NE; Scour-Bos, Novartis Animal Health, IA) administered to late pregnant cows for passive maternal immunization of their calves. The other is a modified-live BCoV (Calf-Guard, Pfizer Animal Health, NY) administered orally to calves at birth to provide active immunization. However, in a field study conducted in Austria, the efficacy of such immunization was questioned. Passive immunization via colostrum has been found to be a reliable mode of vaccinating calves against BCoV, even though antibodies present locally within the gastrointestinal tract, an open-ended system, are typically short lived. Immunizing the pregnant cattle to produce a high colostral IgG1 level will protect the newborn calf against BCoV infection only if there is transfer of passive colostral antibodies within 24 hours after birth. Calves immunized after 24 hours of age may not be protected.

Vaccines differ in injection site reactions, and this can be an important consideration before use. In a preliminary study, the attenuated respiratory strain of the virus was found to be safe for intramuscular administration in cattle. In another trial, about 50% of cows vaccinated with inactivated BCoV and bacterial component vaccine became lame and developed myositis.

**Antigenic variation among bovine enteropathogenic and respiratory coronaviruses**

Previous reports have demonstrated that BCoV replicates in the upper respiratory tract of gnotobiotic calves following experimental inoculation. Moreover, Hasoksuz and colleagues reported that most (9 of 10) BRCoV strains isolated from the nasal passages of cattle entering feedlots in Ohio were similar to reference strains of BECoV previously isolated from calves with diarrhea and adult cattle with winter dysentery. This finding suggests that BRCoV and BECoV are antigenically related and cross-reactive, therefore vaccines developed to protect against enteric strains may also protect against respiratory tract strains of BCoV if administered intranasally. However, BECoV isolates are antigenically classified among 3 subgroups 1–3 using a polyclonal antiserum against the Mebus strain of BCoV. Antigenic Group 3 is the predominant BECoV presently circulating in the United States. Recent calf diarrhea isolates of BECoV are not blocked in hemagglutination-inhibition test by polyclonal antiserum prepared against antigenic Group 1 (Mebus isolate of BECoV). From the list of commercially available BECoV vaccines listed previously, only one (Guardian, Intervet/Schering-Plough Animal Health, NE) contains both antigenic variants of BECoV.

**Vaccine for bovine respiratory coronaviruses**

Modern vaccination programs using multivalent killed or modified-live viral vaccines and attenuated bacterial antigen have been associated with a decrease in BRDC incidence and prevalence; however, none of the commercially available vaccines are labeled for prevention of BRCoV. Protection of the respiratory tract from BRCoV has not been well studied except for one trial in which extralabel use of the
modified-live coronavirus and rotavirus vaccine in feedlot calves administered intranasally significantly decreased the subsequent rate of treatment for respiratory disease in cattle that had relatively low serum antibody titers against BCoV at arrival. More specifically, there was an overall reduction of 26% among vaccinated calves treated for BRDC on entry to the feedlot. Furthermore, BCoV vaccinated calves with detectable intranasal BCoV had a 36% reduction in treatment for BRDC, and those with low antibody titers at arrival had 42% reduction, compared with unvaccinated calves. Although the 26% and 36% reduction was not statistically significant, it was considered clinically significant. The association between antibody titers against BCoV at feedlot arrival seems to correlate with protection from respiratory tract infection, and may promote higher weight gains and reduce virus shedding in nasal secretions. In one study, feedlot cattle that had BCoV antibody titers of greater than 1600 did not shed BCoV fecally or nasally.

In the future, BCoV vaccines may be needed to decrease the economic losses due to BCoV infection in feedlot cattle. It has been suggested recently that feedlot calves should be vaccinated against BCoV at least 3 weeks before shipping to induce a serum IgG GMT of 1860 or more, to provide protection from BCoV infection and its direct or combined effects with other pathogens of BRDC. It has been suggested that development of an intranasally administered vaccine against BCoV, either by itself or combined with BHV-1, may have an added or synergistic effect in reducing incidence and subsequent treatment for BRDC in feedlot cattle.

SUMMARY

Bovine coronavirus is widespread in the cattle industry and is associated with significant economic losses. Clinical syndromes associated with BCoV (calf diarrhea, pneumonia in calves and adult cattle, winter dysentery, and combined pneumonia and diarrhea in young and adult cattle) are due to the virus tropism for the intestinal tract, nasal passages, proximal trachea, and lungs.

Only 4 BCoV isolates have been completely sequenced and thus, the information about the genetics of the virus is still limited. The coronaviruses responsible for enteric and respiratory syndromes in adult cattle and calves are closely related antigenically and genetically, and can be reproduced experimentally. From a vaccination point of view, the enteropathogenic and respiratory BCoV have not been clearly differentiated; however, they do cross-react to a great extent.

It is likely that BCoV work synergistically with other pathogens of the bovine respiratory tract in combination with various stressors to allow bacterial or viral colonization of the lungs, thus leading to development of BRDC. In calves, lack of colostral immunity is an important predisposing factor in the development of most infectious diseases, including diarrhea and respiratory tract infection caused by BCoV. Inclement weather is an important environmental stressor contributing to outbreaks of winter dysentery in dairy cattle.

There is a growing body of evidence in support of a causal relationship between BCoV and BRDC by predisposing or directly inducing lower respiratory tract disease, leading to poor growth performance in feedlot cattle and calves. This issue must be considered in disease prevention or preconditioning programs in the near future. The emergence of the respiratory tract infections caused by BRCoV in the cattle industry warrants timed, active immunization with appropriate antigens (antigenic Groups 1 and 3) to prevent this infection in stocker and feedlot cattle. Current strategies to prevent BCoV-induced enteritis in calves consist in vaccinating the late pregnant cows to provide passive colostral protection.
REFERENCES


18. Lin XQ, O’Reilly KL, Storz J. Antibody responses of cattle with respiratory coronavirus infections during pathogenesis of shipping fever pneumonia are lower


134. de Leeuw PW, Tiessink JW. Laboratory experiments on oral vaccination of calves against rotavirus or coronavirus induced diarrhea. Zentralbl Veterinarmed B 1985;31(1):55–64.


